Literature DB >> 7737300

Intranasal immunization with liposomes induces strong mucosal immune responses in mice.

J Vadolas1, J K Davies, P J Wright, R A Strugnell.   

Abstract

BALB/c mice were immunized intranasally with either soluble ovalbumin (OVA) or OVA entrapped in liposomes. The effect of adding Sigma cholera toxin B subunit (sCT-B), which contained low amounts of cholera holotoxin (CT), or recombinant CT-B (rCT-B) which was free from CT, as mucosal adjuvants was also investigated. The mucosal [lung enzyme-linked immunospot assay (ELISPOT), lung washing] and systemic (serum antibody and spleen ELISPOT) responses of immunized mice to OVA and CT-B were determined. Results showed that soluble OVA and liposome-entrapped OVA were poor inducers of mucosal or systemic responses unless CT-B was added as adjuvant. The types of responses augmented by sCT-B and rCT-B were different. CT-B containing low levels of CT (i.e. sCT-B) boosted both mucosal and systemic IgA and IgG responses, whereas rCT-B only increased IgG responses, unless antigen was entrapped in liposomes. Although rCT-B was unable to adjuvant IgA responses against soluble OVA, it was able to induce IgA responses against itself. These data show that mucosal responses can be increased by addition of CT-B containing low levels of CT to antigen preparations given intranasally, suggesting a direct role for CT-A in isotype switching. Furthermore, the ability of CT-B to adjuvant IgA responses against added antigens and its ability to induce responses against itself appear to be separate phenomena. The results from this study should assist the rational formulation of mucosal vaccines which induce potent mucosal and systemic immune responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737300     DOI: 10.1002/eji.1830250417

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice.

Authors:  B Liang; L Hyland; S Hou
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.

Authors:  Kosuke Kataoka; Kohtaro Fujihashi; Keita Oma; Yoshiko Fukuyama; Susan K Hollingshead; Shinichi Sekine; Shigetada Kawabata; Hiro-O Ito; David E Briles; Kazunori Oishi
Journal:  Infect Immun       Date:  2011-05-02       Impact factor: 3.441

5.  Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits.

Authors:  E Harokopakis; G Hajishengallis; T E Greenway; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

6.  Fusobacterium nucleatum envelope protein FomA is immunogenic and binds to the salivary statherin-derived peptide.

Authors:  Hidetaka Nakagaki; Shinichi Sekine; Yutaka Terao; Masahiro Toe; Muneo Tanaka; Hiro-O Ito; Shigetada Kawabata; Satoshi Shizukuishi; Kohtaro Fujihashi; Kosuke Kataoka
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

7.  A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.

Authors:  Tatsuya Fukuiwa; Shinichi Sekine; Ryoki Kobayashi; Hideaki Suzuki; Kosuke Kataoka; Rebekah S Gilbert; Yuichi Kurono; Prosper N Boyaka; Arthur M Krieg; Jerry R McGhee; Kohtaro Fujihashi
Journal:  Vaccine       Date:  2008-07-14       Impact factor: 3.641

8.  Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations.

Authors:  Mohamed A EL-Malky; Saeed A Al-Harthi; Raafat T Mohamed; Mohamed A EL Bali; Niveen S Saudy
Journal:  Parasitol Res       Date:  2014-04-13       Impact factor: 2.289

9.  Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.

Authors:  Praveen Mannam; Kevin F Jones; Bruce L Geller
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

10.  Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection.

Authors:  R Weltzin; B Guy; W D Thomas; P J Giannasca; T P Monath
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.